FDG PET/CT - Not PSMA Trendy, but Available, Comfortable, and Complementary

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2021 Oct 19

PMID 34665121

Authors

Robert J Hamilton

Affiliations

Soon will be listed here.

References

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

Jadvar H . Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013; 40 Suppl 1:S5-10. PMC: 3681838. DOI: 10.1007/s00259-013-2361-7. View

Jadvar H, Desai B, Ji L, Conti P, Dorff T, Groshen S . Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012; 37(7):637-43. PMC: 3375600. DOI: 10.1097/RLU.0b013e318252d829. View

Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H . A Prospective Trial of Ga-PSMA and F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clin Cancer Res. 2020; 26(17):4551-4558. DOI: 10.1158/1078-0432.CCR-20-0587. View

Beauregard J, Blouin A, Fradet V, Caron A, Fradet Y, Lemay C . FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging. 2015; 15:2. PMC: 4352558. DOI: 10.1186/s40644-015-0038-0. View

Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallee E, Bergeron M . GLUT1 expression in high-risk prostate cancer: correlation with F-FDG-PET/CT and clinical outcome. Prostate Cancer Prostatic Dis. 2020; 23(3):441-448. DOI: 10.1038/s41391-020-0202-x. View

McGeorge S, Kwok M, Jiang A, Emmett L, Pattison D, Thomas P . Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review. Adv Urol. 2021; 2021:1544208. PMC: 8387192. DOI: 10.1155/2021/1544208. View

Fourquet A, Rosenberg A, Mena E, Shih J, Turkbey B, Blain M . A Comparison of F-DCFPyL, F-NaF, and F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. J Nucl Med. 2021; 63(5):735-741. DOI: 10.2967/jnumed.121.262371. View

Bakht M, Lovnicki J, Tubman J, Stringer K, Chiaramonte J, Reynolds M . Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for F-FDG Imaging of PSMA-Suppressed Tumors. J Nucl Med. 2019; 61(6):904-910. PMC: 7262227. DOI: 10.2967/jnumed.119.231068. View

10.

Otis-Chapados S, Ringuette Goulet C, Dubois G, Lavallee E, Dujardin T, Fradet Y . F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Can Urol Assoc J. 2021; 15(10):301-307. PMC: 8525520. DOI: 10.5489/cuaj.7107. View